Zymeworks’ (ZYME) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Zymeworks (NASDAQ:ZYME) in a report issued on Friday,Weiss Ratings reports.

A number of other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Zymeworks from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 19th. B. Riley raised Zymeworks to a “strong-buy” rating in a report on Thursday, October 9th. Finally, HC Wainwright upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Zymeworks Stock Up 1.9%

Shares of ZYME stock opened at $17.74 on Friday. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $19.50. The company has a fifty day moving average price of $16.18. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -18.29 and a beta of 1.51.

Zymeworks (NASDAQ:ZYME) last issued its earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. The business had revenue of $4.40 million during the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.